| |
BMI ≤ 25 (n = 60; 42%)
|
BMI > 25 (n = 81; 58%)
|
|---|
|
OR
|
95% CI
|
OR
|
95% CI
|
|---|
|
Clinical response
|
|
Any csDMARD
|
1.10
|
0.33–3.58
|
7.86
|
2.39–25.78*
|
|
MTX [± SSZ]
|
1.04
|
0.25–4.25
|
9.82
|
2.13–45.20*
|
|
SSZ
|
1.18
|
0.25–5.63
|
6.86
|
1.85–25.40*
|
|
Remission
|
|
Any csDMARD
|
0.76
|
0.20–2.86
|
4.84
|
1.09–21.36*
|
|
MTX [± SSZ]
|
0.60
|
0.11–3.18
|
5.56
|
0.84–36.52
|
|
SSZ
|
0.99
|
0.17–5.64
|
4.35
|
0.77–24.54
|
- The adjusted multivariable logistic regression analysis included 141 patients. Two different models are presented for the following outcomes: clinical response and remission. Odds ratio (OR) and 95% confidence interval (CI) were calculated. All models were adjusted for age, gender, disease duration, HLA-B27, baseline BASDAI and CRP. *p value < 0.05 was considered statistically significant. BMI body mass index, HLA-B27 human leucocyte antigen B27, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine
